Navigation Links
Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing
Date:2/10/2010

NEW YORK, Feb. 10 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS), a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease ("AD"), announced today that several of its significant shareholders (the "Interested Shareholders") have agreed in principle to provide interim funding to the Company and assist the Company in its efforts to restructure its balance sheet.  The Company has initiated discussions with the Interested Shareholders regarding a potential equity financing to fund operations for a longer period than that covered by the interim funding. The contemplated transactions are subject to negotiation and execution of definitive agreements.

Appointment of New Directors

In connection with the contemplated financings, the Interested Shareholders will be given the right to appoint three new members to a newly constituted Board of Directors of the Company. Recently, the Company disclosed that its former independent directors resigned their positions because of a lack of funding to pay for directors and officers liability insurance. The Interested Investors intend to nominate suitable candidates to fill the Board vacancies shortly. The Company intends to seek the approval of its shareholders to a resolution amending the Company's certificate of incorporation to reduce the number of seats on the Board of Directors to five members.

Management Changes

Dr. Daniel Chain has agreed to resign from his position as Chief Executive Officer and assume the position of Chief Scientific Officer so that he may focus his time on advancing the Company's pipeline programs. He will remain Chairman of the Board of Directors. Elliot Maza will remain President and CFO and a m
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. China YCT International Group, Inc. Announces That the State Intellectual Property Office of the Peoples Republic of China has Approved a Patent to its Operating Subsidiary, Shandong Spring Pharmaceutical Co. Ltd.
2. BIO Ventures for Global Health Chosen to Administer the GSK and Alnylam Intellectual Property Pool
3. Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property
4. Finn, Warnke & Gayton Announces A New Service For Biotechnology Firms - A Platform To Sell Intellectual Property
5. Veteran Intellectual Property Team Joins Brown Rudnick
6. EPIX Pharmaceuticals, Inc. Announces the PRX-00023 Therapeutics CNS Program in Phase 2b/3 Will Be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
7. Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory Indication Will Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 Auction
8. Hill-Rom Announces Sale of Negative Pressure Wound Therapy Intellectual Property
9. Thomson Reuters Commemorates World IP Week with Series of Strategic Intellectual Property Seminars Across the U.S.
10. Cancer Advances Acquires the Intellectual Property for a Suite of Products that Enhance the Immune System in Treatment of Gastric, Pancreatic, and Colorectal Cancers
11. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... The report “Service Quality ... by Product Type & Provider Type - ... defines and segments the market with an ... , Browse 152 market data tables, 19 ... TOC on “Service Quality Management (SQM) and ...
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... Inc. (NYSE: MDT ) has submitted ... and Drug Administration (FDA) for the use of ... system (including a newly developed catheter) for use ... delivered intravenously to patients with pulmonary arterial hypertension.   ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 /PRNewswire/ ... company advancing patient care in critical areas, announced the ... of common stock, and warrants to purchase up to ... offering price of $4.00 per share and $.01 per ... of $5.00, are exercisable immediately, and expire 5 years ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that the Company closed ... Oracle Investment Management, Jack W. Schuler , ... proceeds were $10.5 million, before offering expenses.  The ... general corporate purposes. Under the terms ...
Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... New Best Practice Statements Were Presented at the ... YOKNEAM, Israel and PLYMOUTH MEETING, Pennsylvania, May 21 ... announced today that the,American Urological Association has introduced ... The guidelines state,that cryoablation is a treatment option ...
... Sweden, May 21 At the 14th ... 18-22, over 500 participants,including neurosurgeons, radiation oncologists ... for treatment of tumors and other,brain disorders ... in Quebec,Canada. During the meeting, 260 oral ...
... First Diagnostic Test Based on Company,s microRNA Technology Submitted for, Regulatory Approval to ... ... Validate and Offer Tests Based ... Two Additional microRNA-Related ...
Cached Biology Technology:American Urological Association (AUA) Clinical Guidelines Recognizes Cryotherapy as Treatment Option for Prostate Cancer Patients 2American Urological Association (AUA) Clinical Guidelines Recognizes Cryotherapy as Treatment Option for Prostate Cancer Patients 3Elekta Sees Record Attendance and Record Number of Submitted Abstracts at International Leksell Gamma Knife(R) Society Meeting in Quebec, Canada 2Elekta Sees Record Attendance and Record Number of Submitted Abstracts at International Leksell Gamma Knife(R) Society Meeting in Quebec, Canada 3Rosetta Genomics Reports First Quarter 2008 Financial Results 2Rosetta Genomics Reports First Quarter 2008 Financial Results 3Rosetta Genomics Reports First Quarter 2008 Financial Results 4Rosetta Genomics Reports First Quarter 2008 Financial Results 5Rosetta Genomics Reports First Quarter 2008 Financial Results 6Rosetta Genomics Reports First Quarter 2008 Financial Results 7Rosetta Genomics Reports First Quarter 2008 Financial Results 8Rosetta Genomics Reports First Quarter 2008 Financial Results 9Rosetta Genomics Reports First Quarter 2008 Financial Results 10
(Date:12/24/2014)... its launch in December 2014, the 1U™ ... pain of trying to remember their usernames and passwords ... fused to their smartphones. To assist people who have ... , the company that created 1U and focuses on ... app for free. 1U is an identity ...
(Date:12/22/2014)...  NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces it ... Apollo Robbins for the 2015 International CES debut ... Apollo Robbins will be at the NXT-ID ... some of his famous theft techniques to visiting media ...
(Date:12/22/2014)... 22, 2014 Research and Markets ... addition of the "The Global Watermarking ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... overview of the global digital media watermarking ... and monitor piracy by securely and invisibly ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4The Global Watermarking and Fingerprinting Markets 2
... the full text of the press releases and the ... note that all news releases are embargoed until Thursday, ... BREAST CANCER PATIENTS WHO WILL RESPOND TO CHEMOTHERAPY , ... genetic signature that can predict which breast cancer patients ...
... are characterized by poor vegetative cover, strong winds, ... this context, the land resources of Abu Dhabi ... to various land degradation stresses, including wind erosion, ... land resources of Abu Dhabi Emirate, land degradation ...
... in French . , Montreal, May 6, ... pregnancy, affecting more than 80 percent of future mothers. ... that hospitalization is required. Yet a new ... appears effective in improving symptoms more quickly and provides ...
Cached Biology News:IMPAKT -- Breast cancer conference highlights 2Wind, salt and water are leading indicators of land degradation in Abu Dhabi 2Treatment for extreme nausea, vomiting during pregnancy 2
Bis-Acrylamide (bis) is a monomer used as a crosslinker with acrylamide to form polyacrylamide electrophoretic gels. This 2% bis solution is supplied as 500 ml....
Anti-human VEGFR-2/KDR (Protein-A Purified) Polyclonal Antibody...
Mouse monoclonal antibody to Lats2....
Goat polyclonal to Lipocalin 2...
Biology Products: